Stoneridge Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Stoneridge Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,144	Closed	-$331K	–	109
2022 Q3	$331K	Sell	1,144 -851	-43%	-$245K	0.19%	79
2022 Q2	$562K	Buy	+1,995	New	+$534K	0.31%	75
2022 Q1	–	Sell	-1,138	Closed	-$250K	–	132
2021 Q4	$250K	Sell	1,138 -2,600	-70%	-$506K	0.12%	103
2021 Q3	$678K	Buy	3,738 +1,550	+71%	+$303K	0.34%	73
2021 Q2	$441K	Hold	2,188	–	–	0.21%	85
2021 Q1	$470K	Buy	2,188 +450	+26%	+$98.8K	0.25%	81
2020 Q4	$411K	Buy	+1,738	New	+$399K	0.24%	89

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Stoneridge Investment Partners's VRTX Position: Q4 2022 in Review

Stoneridge Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 1,144 shares — an estimated $331K sold.

Stoneridge Investment Partners first reported a position in VRTX in Q4 2020 and held it in 7 quarters. The position peaked at $678K in Q3 2021. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Stoneridge Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Stoneridge Investment Partners sold 1,144 Vertex Pharmaceuticals shares in Q4 2022, an estimated $331K.
Stoneridge Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Stoneridge Investment Partners's Vertex Pharmaceuticals position peaked at $678K in Q3 2021.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Stoneridge Investment Partners's 13F filing for Q4 2022, filed 6 Feb 2023.